

Resource Summary Report

Generated by [dkNET](#) on Aug 24, 2026

MSIsensor

RRID:SCR_006418

Type: Tool

Proper Citation

MSIsensor (RRID:SCR_006418)

Resource Information

URL: <https://github.com/ding-lab/msisensor>

Proper Citation: MSIsensor (RRID:SCR_006418)

Description: A C++ software program for automatically detecting somatic and germline variants at microsatellite regions. It computes length distributions of microsatellites per site in paired tumor and normal sequence data, subsequently using these to statistically compare observed distributions in both samples.

Abbreviations: MSIsensor

Resource Type: software resource

Defining Citation: [PMID:24371154](#)

Keywords: c++, somatic variant, germline variant, microsatellite, bio.tools

Related Condition: Tumor, Normal

Availability: Copyrighted, See LICENSE

Resource Name: MSIsensor

Resource ID: SCR_006418

Alternate IDs: biotools:msisensor, OMICS_02192

Alternate URLs: <https://bio.tools/msisensor>

Record Creation Time: 20220129T080236+0000

Record Last Update: 20260815T182319+0000

Ratings and Alerts

No rating or validation information has been found for MSIsensor.

No alerts have been found for MSIsensor.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 168 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hlevnjak M, et al. (2026) Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experience. International journal of cancer, 158(6), 1675.

Wang Y, et al. (2026) A 15-layer multi-omics analysis of gastric cancer ecotypes provides therapeutic insights. Cell reports. Medicine, 7(5), 102756.

Siddiqui MT, et al. (2026) Effect of chemotherapy on passenger mutations in metastatic colorectal cancer. Molecular oncology, 20(2), 248.

Misyura M, et al. (2026) Germline Pathogenic Variants in Homologous Recombination Pathway Genes Are Frequent in Pancreatobiliary Ampullary Carcinoma. JCO precision oncology, 10(4), e2500596.

Gu S, et al. (2026) Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial. Nature cancer, 7(1), 60.

Zhao F, et al. (2026) Genetic landscape of Chinese colorectal cancer: insights into germline and somatic mutations. BMC cancer, 26(1).

Zennami K, et al. (2026) Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy. Cancer science, 117(5), 1469.

Nones K, et al. (2026) Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities. Genome medicine, 18(1).

Chang HY, et al. (2026) Uniform Processing of Diverse Sequencing Data: A Cross-Population Comparison of Colon Cancer Genomic Landscapes from The Cancer Genome Atlas and a Chinese Cohort. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 35(5), 762.

Guercio BJ, et al. (2026) Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. Clinical cancer research : an

official journal of the American Association for Cancer Research, 32(8), 1434.

Kim K, et al. (2025) Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma. *European urology*, 87(3), 342.

Li Y, et al. (2025) Spatial Transcriptomics and snRNA-seq Expose CAF Niches Orchestrating Dual Stromal-Immune Barriers in Hepatocellular Carcinoma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(48), e14661.

Domenico D, et al. (2025) Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology. *Nature communications*, 16(1), 10649.

Zhou B, et al. (2025) A novel algorithm for the detection of microsatellite instability in endometrial cancer using next-generation sequencing data. *Oncology letters*, 29(2), 86.

Egea-Rodriguez S, et al. (2025) RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma. *Clinical and translational medicine*, 15(1), e70094.

Joly F, et al. (2025) Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial. *Nature communications*, 16(1), 7950.

Huo ??? X, et al. (2025) Genome-wide Genetic Mutations Accumulated in Pigs Genome-edited for Xenotransplantation and Their Filial Generation. *Genomics, proteomics & bioinformatics*, 23(4).

Li J, et al. (2025) The Expression Characteristics of the RBFOX1 Gene in Colorectal Cancer. *Technology in cancer research & treatment*, 24, 15330338251333695.

Unger M, et al. (2025) Deep Learning for Biomarker Discovery in Cancer Genomes. *bioRxiv* : the preprint server for biology.

Yazaki S, et al. (2025) AlphaMissense for Identifying Pathogenic Missense Mutations in DNA Damage Repair Genes in Cancer. *JCO precision oncology*, 9, e2400908.